Clinical Trials
14 trialsNCT00092222 2026-05-22
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04554914 2026-04-27
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT03467867 2026-04-06
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
Phase 2 Active not recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT02861417 2026-02-17
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT02690545 2026-01-06
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03602157 2026-01-06
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT00710892 2025-07-11
CASPALLO
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01494103 2025-07-11
DOTTI
Baylor College of Medicine
Phase 1 Active not recruiting
NCT02663297 2025-05-15
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting